PRDX6 Antibody

What is PRDX6 and why is it important in cellular research?

PRDX6 is a bifunctional enzyme possessing both peroxidase activity and calcium-independent phospholipase A2 (iPLA2) activity. Unlike other members of the peroxiredoxin family, PRDX6 is the only 1-Cys peroxiredoxin in mammals. Its importance stems from its dual role in cellular antioxidant defense and phospholipid metabolism .

PRDX6 protects cells against oxidative stress by reducing hydrogen peroxide (H₂O₂) and various lipid peroxides. Studies have demonstrated that PRDX6 overexpression attenuates H₂O₂-induced apoptosis, while PRDX6 knockdown increases cellular sensitivity to oxidative damage . In experimental models, PRDX6-overexpressing HeLa cells showed significantly reduced apoptosis when exposed to 500 μM H₂O₂ compared to mock-transfected cells, confirming its protective role .

The protein is highly expressed in liver tissue and plays a crucial role in maintaining cellular redox homeostasis. Deficiency in PRDX6 has been linked to impaired homeostasis and increased rates of cell death/apoptosis under oxidative stress conditions .

What are the recommended applications for PRDX6 antibodies?

PRDX6 antibodies have been validated for multiple research applications with specific recommended dilutions:

It's important to note that these dilutions should be optimized for each specific experimental system to obtain optimal results. Sample-dependent variations may require adjustments to these recommended parameters .

What cellular models are most suitable for PRDX6 antibody validation?

Based on the comprehensive testing data available, several cell lines have been successfully used to validate PRDX6 antibodies:

Additionally, pig brain tissue has been validated for Western blot analysis, and human liver tissue has been successfully used for immunohistochemistry applications . This wide range of validated models provides researchers with multiple options for experimental design based on their specific research focus.

How should researchers interpret bands observed in Western blots using PRDX6 antibodies?

When using PRDX6 antibodies in Western blot applications, researchers should expect to observe bands at 25-30 kDa, corresponding to the calculated molecular weight of PRDX6 (25 kDa from its 224 amino acid sequence) .

The slight variation in observed molecular weight can result from:

• Post-translational modifications

• Differential sample preparation methods

• Gel concentration and running conditions

• The presence of dimeric forms of PRDX6 under certain redox conditions

It's important to note that PRDX6 can form dimers under certain conditions, which may be detected at approximately 50 kDa in non-reducing conditions . When analyzing PRDX6 expression or modifications (such as hyperoxidation), researchers should include appropriate positive and negative controls to ensure accurate interpretation of results.

How does hyperoxidation affect PRDX6 function and antibody detection?

Hyperoxidation of PRDX6 represents a critical regulatory mechanism with significant implications for cellular function under oxidative stress. Unlike 2-Cys peroxiredoxins whose hyperoxidation is reversible in vivo, PRDX6 hyperoxidation is irreversible . This distinction has profound implications for cellular response to oxidative stress.

At high H₂O₂ concentrations (>100 μM), PRDX6 becomes hyperoxidized at its catalytic cysteine (Cys47) to sulfinic (-SO₂H) or sulfonic (-SO₃H) forms. This hyperoxidation has two major functional consequences:

• Loss of peroxidase activity: Hyperoxidation renders PRDX6 unable to reduce peroxides, diminishing its antioxidant capacity.

• Enhanced iPLA₂ activity: Interestingly, hyperoxidation increases the calcium-independent phospholipase A₂ activity of PRDX6 .

For antibody detection, researchers should note that the hyperoxidized form of PRDX6 demonstrates distinct localization patterns compared to the reduced form. Confocal microscopy studies have shown that hyperoxidized PRDX6 localizes predominantly in the nucleus, while the non-hyperoxidized form is more evenly distributed throughout the cell . Specialized antibodies that specifically recognize the hyperoxidized form (Prdx6-SO₂H/SO₃H) are available and should be used alongside regular PRDX6 antibodies when studying oxidative stress responses.

What is the relationship between PRDX6 hyperoxidation and cell cycle regulation?

Research has demonstrated a critical link between PRDX6 hyperoxidation and cell cycle regulation, particularly at the G2/M transition. Experimental evidence indicates that H₂O₂-induced cell cycle arrest correlates specifically with PRDX6 hyperoxidation and increased iPLA₂ activity .

This arrest mechanism involves several coordinated molecular events:

PRDX6 hyperoxidation appears to function as a molecular switch that transitions the protein from an antioxidant defender to a mediator of cell cycle arrest under high oxidative stress conditions. This dual functionality may represent an evolved mechanism to prevent cells with oxidative damage from progressing through mitosis, thereby reducing the risk of propagating damaged genetic material .

For researchers investigating cell cycle dynamics in response to oxidative stress, monitoring both PRDX6 hyperoxidation status and iPLA₂ activity provides valuable insights into the cellular decision-making process between continued proliferation and cell cycle arrest.

What experimental approaches can distinguish between PRDX6's peroxidase and phospholipase activities?

Distinguishing between the dual enzymatic activities of PRDX6 requires specialized experimental approaches. Below are methodological strategies researchers can implement:

For peroxidase activity measurement:

• Peroxide consumption assay: Monitor the decrease in H₂O₂ concentration using ferrous oxidation-xylenol orange (FOX) assay in the presence of purified PRDX6.

• Site-directed mutagenesis: Compare wild-type PRDX6 with C47A mutant (peroxidase-inactive) to confirm specificity.

• Thiol-specific labeling: Use biotinylated iodoacetamide to label the reduced form of Cys47, providing quantitative assessment of peroxidase cycling.

For iPLA₂ activity measurement:

• Fluorescent phospholipid substrates: Use 1-palmitoyl-2-(6,7-dibutoxy-coumarin-3-yl)-phosphatidylcholine to measure PLA₂ activity through fluorescence emission.

• H26A mutant comparison: Compare wild-type PRDX6 with H26A mutant (phospholipase-inactive) while maintaining peroxidase function.

• MJ33 inhibitor studies: Use the specific iPLA₂ inhibitor MJ33 to selectively block phospholipase activity without affecting peroxidase function.

When designing experiments to evaluate these distinct functions, researchers should consider that PRDX6's phospholipase activity increases substantially following hyperoxidation of Cys47 . This connection between the two activities creates a regulatory mechanism whereby high oxidative stress switches PRDX6 from an antioxidant mode to a signaling mode through enhanced phospholipase activity.

How do structural changes in PRDX6 during its catalytic cycle affect antibody recognition?

The catalytic cycle of PRDX6 involves significant structural transitions that can impact antibody recognition. Recent research indicates that PRDX6's peroxidase activity is a redox-based, conformation-driven process that involves monomer-dimer transitions .

The key structural features affecting antibody recognition include:

• Monomer-dimer equilibrium: While the crystal structure of recombinant human PRDX6 has been resolved as a dimer, solution structures reveal both monomeric and dimeric forms. The oligomeric state changes as a function of the peroxidatic thiol's redox state .

• Conformational changes around Cys47: The catalytic cysteine (Cys47) undergoes substantial local conformational changes during the catalytic cycle, potentially altering epitope accessibility.

• Redox-dependent surface exposure: Oxidation status affects surface epitope exposure, with hyperoxidized PRDX6 potentially exposing different epitopes compared to reduced PRDX6.

When selecting antibodies for specific experimental purposes, researchers should consider:

• Antibodies raised against different regions of PRDX6 may have varying abilities to recognize the protein in different redox states

• Polyclonal antibodies may provide more consistent detection across redox states compared to monoclonal antibodies targeting specific epitopes

• For studies specifically focused on the catalytic cycle, using antibodies targeting regions distant from the catalytic site may provide more consistent detection

How can researchers optimize immunoprecipitation protocols for PRDX6 interaction studies?

Optimizing immunoprecipitation (IP) protocols for PRDX6 requires careful consideration of its structural properties and potential interaction partners. Based on validated protocols, the following methodological approach is recommended:

Optimized PRDX6 Immunoprecipitation Protocol:

• Cell lysis optimization:

  • Use a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, with freshly added protease inhibitors

  • Critical addition: Include 10 mM N-ethylmaleimide (NEM) to prevent post-lysis oxidation of thiols

  • For oxidation studies, add 1 mM sodium orthovanadate to inhibit tyrosine phosphatases

• Antibody selection and quantity:

  • Recommended antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • For hyperoxidation studies, use specialized antibodies recognizing Prdx6-SO₂H/SO₃H forms

  • Test both N-terminal and C-terminal targeting antibodies, as epitope accessibility varies with redox state

• Bead selection considerations:

  • Protein A/G beads work effectively for most PRDX6 antibodies

  • For studies focusing on dimeric PRDX6, consider crosslinked beads to reduce heavy chain interference

• Washing conditions:

  • Use stringent washing (higher salt concentrations) for interaction studies to reduce non-specific binding

  • For structural studies, gentler washing conditions help maintain protein-protein interactions

• Elution strategies:

  • Acidic glycine elution (pH 2.5) followed by immediate neutralization

  • Alternatively, direct elution in SDS sample buffer for maximum recovery

This optimized protocol has been successfully used with HAP1 cells and can be adapted for other cell types. When studying PRDX6 interactions, researchers should consider the redox state of the cellular environment, as this significantly impacts PRDX6's interaction network.

How can researchers address non-specific binding issues with PRDX6 antibodies?

Non-specific binding is a common challenge when working with PRDX6 antibodies. Several methodological approaches can minimize these issues:

Western Blot Optimization:

• Blocking optimization: Test 5% skim milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween 20) as proven effective for PRDX6 antibodies .

• Antibody dilution: Use higher dilutions (1:5000-1:50000) for Western blot applications to reduce non-specific binding .

• Wash stringency: Incorporate additional washing steps with TBS-T to remove loosely bound antibodies.

Immunohistochemistry Considerations:

• Antigen retrieval: For optimal results in tissue sections, use TE buffer pH 9.0; alternatively, citrate buffer pH 6.0 can be used .

• Antibody concentration: Use IHC-specific dilutions (1:1000-1:4000) to balance signal strength and specificity .

• Tissue preparation: Include additional blocking steps with normal serum from the species of secondary antibody origin.

Immunofluorescence Refinement:

• Fixation method: Compare paraformaldehyde fixation with methanol fixation, as PRDX6 epitope accessibility may differ between methods.

• Permeabilization optimization: Test different detergent concentrations (0.1-0.5% Triton X-100) to balance cell membrane permeabilization with protein structure preservation.

• Signal amplification: For low-abundance detection, consider using tyramide signal amplification while maintaining antibody specificity.

When evaluating specificity, researchers should always include appropriate controls, including PRDX6 knockdown/knockout samples when available, to conclusively distinguish between specific and non-specific signals.

How can researchers differentiate between PRDX6 and other peroxiredoxin family members?

Differentiating PRDX6 from other peroxiredoxin family members requires careful experimental design due to structural similarities within this protein family. The following methodological approach ensures specific PRDX6 detection:

Antibody Selection Strategy:

• Epitope targeting: Select antibodies raised against unique regions of PRDX6 not conserved in other PRDXs.

• Validation testing: Confirm antibody specificity using protein arrays. High-quality PRDX6 antibodies should be validated against arrays containing multiple peroxiredoxin family members .

• Cross-reactivity assessment: Test for cross-reactivity with recombinant PRDX1-5 proteins in parallel with PRDX6.

Experimental Differentiation Methods:

• Molecular weight discrimination: PRDX6 migrates at 25-30 kDa, which can help distinguish it from some other family members with different molecular weights .

• Functional assays: Leverage PRDX6's unique phospholipase A2 activity, which is absent in other peroxiredoxins, using specific substrates.

• Subcellular localization: While there is some overlap in localization patterns, hyperoxidized PRDX6 shows distinctive nuclear localization compared to other PRDXs .

Advanced Differentiation Techniques:

• Two-dimensional electrophoresis: Separate PRDXs based on both isoelectric point and molecular weight for enhanced discrimination.

• PRDX6-specific inhibitors: Use MJ33 (iPLA2 inhibitor) which specifically inhibits PRDX6's phospholipase activity but not other PRDXs.

• Redox state sensitivity: Exploit PRDX6's unique irreversible hyperoxidation pattern compared to the reversible hyperoxidation of 2-Cys PRDXs .

Researchers should note that the antibody specified in the search results (67499-1-Ig) has been thoroughly validated for PRDX6 specificity through protein array testing against 364 human recombinant protein fragments, ensuring minimal cross-reactivity with other peroxiredoxin family members .

How can PRDX6 antibodies be utilized in studying oxidative stress-related pathologies?

PRDX6 antibodies offer powerful tools for investigating oxidative stress-related pathologies, particularly those involving dysregulated cellular redox homeostasis. Methodological approaches for such studies include:

Tissue-Specific Expression Analysis:

• Comparative IHC profiling: PRDX6 antibodies can be used to compare expression levels across 44 normal human tissues and 20 of the most common cancer types .

• Hyperoxidation mapping: Using specific antibodies against hyperoxidized PRDX6 (Prdx6-SO₂H/SO₃H) to identify tissues experiencing high oxidative stress.

• Subcellular redistribution: Track PRDX6 localization changes in disease states, particularly focusing on nuclear accumulation of hyperoxidized forms .

Mechanism-Focused Applications:

• Cell cycle dysregulation: Investigate the correlation between PRDX6 hyperoxidation and aberrant cell cycle control in cancer cells.

• Dual enzymatic activity: Monitor both peroxidase and phospholipase activities in disease models to determine which function predominates under pathological conditions.

• Protein-protein interaction networks: Use PRDX6 antibodies for immunoprecipitation to identify altered interaction partners in disease states.

Therapeutic Monitoring Applications:

• Oxidative stress biomarker: Quantify hyperoxidized PRDX6 levels as a potential biomarker for oxidative stress severity.

• Treatment response indicator: Monitor changes in PRDX6 expression and hyperoxidation status in response to antioxidant therapies.

• Combinatorial analysis: Pair PRDX6 antibodies with other oxidative stress markers for comprehensive redox status assessment.

The bifunctional nature of PRDX6 makes it particularly valuable for studying diseases where both antioxidant defense and lipid metabolism are implicated, such as neurodegenerative disorders, cardiovascular diseases, and certain cancers where oxidative stress plays a pathogenic role.

What are the emerging techniques for studying PRDX6 structural changes using antibody-based approaches?

Emerging techniques for studying PRDX6 structural dynamics combine traditional antibody-based methods with cutting-edge technologies. These methodological innovations include:

Proximity-Based Structural Analysis:

• Förster resonance energy transfer (FRET): Using fluorescently-labeled PRDX6 antibodies targeting different epitopes to monitor conformational changes during redox cycling.

• Proximity ligation assay (PLA): Detecting specific PRDX6 conformations or interaction partners with single-molecule sensitivity in fixed cells.

• Biolayer interferometry: Measuring binding kinetics of PRDX6 antibodies to different redox states of the protein to infer structural differences.

Advanced Microscopy Applications:

• Super-resolution microscopy: Combining PRDX6 antibodies with techniques like STORM or PALM to visualize nanoscale distribution and oligomerization.

• Live-cell nanobody imaging: Using fluorescently-tagged nanobodies derived from PRDX6 antibodies to track conformational changes in real-time.

• Correlative light and electron microscopy (CLEM): Precisely locating PRDX6 ultrastructural context while preserving functional information.

Mass Spectrometry Integration:

• Crosslinking mass spectrometry: Using antibodies to isolate PRDX6 complexes followed by crosslinking and mass spectrometry to map interaction interfaces.

• Hydrogen-deuterium exchange mass spectrometry: Comparing epitope accessibility in different redox states to infer structural changes.

• Native mass spectrometry: Analyzing antibody-PRDX6 complexes to determine oligomeric state distributions under different conditions.

These emerging techniques are particularly valuable for investigating the monomer-dimer transitions that occur during PRDX6's catalytic cycle, which has been identified as a critical feature of its peroxidase activity regulation . By combining these advanced approaches with traditional antibody applications, researchers can gain unprecedented insights into the structural dynamics of PRDX6 under physiological and pathological conditions.